How to Help Your Patients Save Money on Nivestym: A Provider's Guide to Savings Programs

Financial toxicity — the financial harm caused by the cost of cancer care — is a real and growing clinical concern. For patients prescribed Nivestym (filgrastim-aafi) as part of their cancer treatment, the cost of this specialty biologic can add significant financial stress on top of an already difficult situation. As a provider, understanding the available savings mechanisms can make a meaningful difference in your patients' ability to adhere to their prescribed regimen.

Understanding Nivestym's Cost Structure

When Nivestym launched in 2018, Pfizer priced it at a wholesale acquisition cost (WAC) of $350.40 per 480-mcg prefilled syringe — approximately 30% below Neupogen's WAC at the time. At retail, cash-paying patients may still see prices ranging from approximately $222 for a 300 mcg/0.5 mL syringe to over $445 for a 480 mcg/0.8 mL syringe, and multi-dose vials can exceed $3,000.

Because Nivestym is typically dosed daily for 10 to 14 days per chemotherapy cycle, and patients may receive multiple cycles, the total cost over a course of treatment can be substantial — even for insured patients facing specialty drug copays or coinsurance.

Program 1: Pfizer Oncology Together Copay Program

This is the most impactful savings program available for commercially insured patients on Nivestym.

• Who qualifies: Commercially insured patients (not Medicare, Medicaid, or government insurance)
• Benefit: Patient copay as low as $0 per treatment; maximum savings of $25,000 per calendar year
• Provider role: Healthcare providers can submit the Copay Claim Form on behalf of enrolled patients, streamlining the process
• Contact: 1-800-505-4426 or pfizeroncologytogether.com

Clinical staff should be aware that this program applies regardless of whether the patient is receiving Nivestym in the office setting (Part B) or dispensed at home (specialty pharmacy). The savings mechanism differs slightly by setting — your billing team can assist with the Part B office-setting pathway.

Program 2: Pfizer Patient Assistance Program (PAP)

For uninsured or underinsured patients who cannot afford Nivestym, the Pfizer Patient Assistance Program (PAP) may provide the medication at no cost.

• Who qualifies: Uninsured or underinsured patients meeting income eligibility criteria
• Application: Electronic or phone enrollment; physician signature or provider documentation may be required
• Contact: 1-800-675-8416

Medicare Part B Billing: Optimizing Reimbursement

When Nivestym is administered in your office or a hospital outpatient department, it is typically covered under Medicare Part B. Accurate coding is essential for correct reimbursement and to minimize patient out-of-pocket costs.

• HCPCS code: Q5110 (Injection, filgrastim-aafi, biosimilar, [Nivestym], 1 microgram). Each microgram equals one billing unit.
• JW modifier: Required when there is drug waste (unused drug discarded after administration)
• JZ modifier: Required (as of July 1, 2023) when there is no drug waste — claims submitted without JW or JZ may be rejected
• Reimbursement rate: Medicare reimburses at ASP + 6% for Part B drugs in the office setting

For Medicare patients, the patient's 20% coinsurance on Part B drugs can still be significant. Medigap (Medicare Supplement) plans cover some or all of this coinsurance. Medicare Advantage plans have varying drug coverage. Discuss with your billing team and the patient's supplemental plan.

Third-Party Foundations: Supplemental Assistance

Several independent nonprofit foundations may provide copay or medication cost assistance. Availability of funds changes frequently, so connect your patients to these resources proactively:

• Patient Advocate Foundation (PAF) — patient-advocate.org; co-pay relief programs for cancer medications
• HealthWell Foundation — healthwellfoundation.org; check for open oncology disease funds
• PAN Foundation — panfoundation.org; co-pay and cost-sharing assistance
• CancerCare — cancercare.org; limited copay grants by cancer type

Strategy: Is a Biosimilar Switch More Cost-Effective?

In some cases, a different filgrastim biosimilar may be preferred or required by the patient's insurance formulary — meaning better coverage and lower patient out-of-pocket cost. Before prescribing Nivestym, consider checking the patient's plan formulary for preferred G-CSF agents:

• If the plan prefers Zarxio (filgrastim-sndz) as a Tier 1 or preferred agent, switching can reduce the patient's copay without affecting clinical outcomes
• If Nivestym is preferred by the payer, the Pfizer Oncology Together Copay Program can still minimize patient cost
• Always ensure any biosimilar switch is clinically appropriate for the patient's specific indication before changing the prescription

How medfinder Can Support Your Patients' Access

Even when savings programs reduce cost, patients may still struggle to find a pharmacy that stocks Nivestym. medfinder.com/providers is a service that calls pharmacies near a patient's location to check which ones can fill their Nivestym prescription — reducing the burden on your clinical staff to manage pharmacy hunting calls. See the full provider guide to helping patients find Nivestym for workflow tips.

Key Takeaways for Oncology Providers

• Pfizer Oncology Together can bring commercially insured patients' Nivestym cost to as little as $0 — enroll patients proactively
• Pfizer's PAP provides Nivestym at no cost for income-eligible uninsured/underinsured patients (call 800-675-8416)
• Medicare Part B: use HCPCS Q5110 with JW or JZ modifier to avoid claim rejections
• Third-party foundations (PAF, HealthWell, PAN) can supplement manufacturer assistance for cost-burdened patients
• Check payer formularies before prescribing — a preferred biosimilar may carry lower patient copays for your patient's specific plan